大葉大學圖書館 |

登入

回首頁

Differential sensitivity of Baxdelta...

Chen, Wenjing.

Differential sensitivity of Baxdelta2 positive and negative cells to anti-tumor agent bortezomib in colon cancer.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
書名/作者:	Differential sensitivity of Baxdelta2 positive and negative cells to anti-tumor agent bortezomib in colon cancer.
作者:	Chen, Wenjing.
面頁冊數:	38 p.
附註:	Source: Masters Abstracts International, Volume: 54-06.
Contained By:	Masters Abstracts International54-06(E).
標題:	Biology.
標題:	Molecular biology.
ISBN:	9781321939477
摘要、提要註:	Tumor suppressor Baxdelta2 is a functional Bax isoform that is found in microsatellite unstable (MSI) colon cancer. However, Baxdelta2 proteins are not stable and are prone to be degraded by proteasomes in tumor cells. Bortezomib, a proteasome inhibitor, is an FDA approved anti-cancer drug mainly used for the treatment of myeloma and lymphoma. We tested if Bortezomib can block Baxdelta2 degradation and potentially be beneficial for the treatment of Baxdelta2 positive colon cancer. In this project, we compared the efficacy of Bortezomib-induced cell death in Baxdelta2-positive and Baxdelta2-negative colon cancer cells. We found that Baxdelta2-positive cells were highly sensitive to Bortezomib-induced cell death in comparison with that in Baxdelta2-negative cells. The half maximal inhibitory concentration (IC50) of cell viability for Baxdelta2-positive cells is 11.1 nM, while it is 453.8 nM for Baxdelta2-negative cells. The results indicate that Bortezomib has a selectivity towards Baxdelta2-expressive cells and could be a drug candidate for the treatment of Baxdelta2-positive colon cancer.
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1595295

Differential sensitivity of Baxdelta2 positive and negative cells to anti-tumor agent bortezomib in colon cancer.
Chen, Wenjing.

Differential sensitivity of Baxdelta2 positive and negative cells to anti-tumor agent bortezomib in colon cancer. - 38 p.

Source: Masters Abstracts International, Volume: 54-06.

Thesis (M.S.)--Illinois Institute of Technology, 2015.

Tumor suppressor Baxdelta2 is a functional Bax isoform that is found in microsatellite unstable (MSI) colon cancer. However, Baxdelta2 proteins are not stable and are prone to be degraded by proteasomes in tumor cells. Bortezomib, a proteasome inhibitor, is an FDA approved anti-cancer drug mainly used for the treatment of myeloma and lymphoma. We tested if Bortezomib can block Baxdelta2 degradation and potentially be beneficial for the treatment of Baxdelta2 positive colon cancer. In this project, we compared the efficacy of Bortezomib-induced cell death in Baxdelta2-positive and Baxdelta2-negative colon cancer cells. We found that Baxdelta2-positive cells were highly sensitive to Bortezomib-induced cell death in comparison with that in Baxdelta2-negative cells. The half maximal inhibitory concentration (IC50) of cell viability for Baxdelta2-positive cells is 11.1 nM, while it is 453.8 nM for Baxdelta2-negative cells. The results indicate that Bortezomib has a selectivity towards Baxdelta2-expressive cells and could be a drug candidate for the treatment of Baxdelta2-positive colon cancer.

ISBN: 9781321939477Subjects--Topical Terms:

171887
Biology.

Differential sensitivity of Baxdelta2 positive and negative cells to anti-tumor agent bortezomib in colon cancer.
LDR:01993nam a2200277 4500 001 440908
005 20160422125028.5
008 160525s2015 ||||||||||||||||| ||eng d
020 $a 9781321939477
035 $a (MiAaPQ)AAI1595295
035 $a AAI1595295
040 $a MiAaPQ $c MiAaPQ
100 1 $a Chen, Wenjing. $3 629873
245 1 0 $a Differential sensitivity of Baxdelta2 positive and negative cells to anti-tumor agent bortezomib in colon cancer.
300 $a 38 p.
500 $a Source: Masters Abstracts International, Volume: 54-06.
500 $a Adviser: Jialing Xiang.
502 $a Thesis (M.S.)--Illinois Institute of Technology, 2015.
520 $a Tumor suppressor Baxdelta2 is a functional Bax isoform that is found in microsatellite unstable (MSI) colon cancer. However, Baxdelta2 proteins are not stable and are prone to be degraded by proteasomes in tumor cells. Bortezomib, a proteasome inhibitor, is an FDA approved anti-cancer drug mainly used for the treatment of myeloma and lymphoma. We tested if Bortezomib can block Baxdelta2 degradation and potentially be beneficial for the treatment of Baxdelta2 positive colon cancer. In this project, we compared the efficacy of Bortezomib-induced cell death in Baxdelta2-positive and Baxdelta2-negative colon cancer cells. We found that Baxdelta2-positive cells were highly sensitive to Bortezomib-induced cell death in comparison with that in Baxdelta2-negative cells. The half maximal inhibitory concentration (IC50) of cell viability for Baxdelta2-positive cells is 11.1 nM, while it is 453.8 nM for Baxdelta2-negative cells. The results indicate that Bortezomib has a selectivity towards Baxdelta2-expressive cells and could be a drug candidate for the treatment of Baxdelta2-positive colon cancer.
590 $a School code: 0091.
650 4 $a Biology. $3 171887
650 4 $a Molecular biology. $3 182854
690 $a 0306
690 $a 0307
710 2 $a Illinois Institute of Technology. $b Biological and Chemical Sciences. $3 629874
773 0 $t Masters Abstracts International $g 54-06(E).
790 $a 0091
791 $a M.S.
792 $a 2015
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1595295

筆 0 讀者評論

多媒體

多媒體檔案
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1595295

評論

新增評論分享你的心得

Export

取書館別